Oppenheimer raised the firm’s price target on Rentokil Initial (RTO) to $35 from $30 and keeps an Outperform rating on the shares. The firm notes Rentokil’s Q4 revenues of $1.7B were in line with estimates, driven by improvement in North America Pest Control organic growth. Despite some weather-related disruption in NA in January, and increased uncertainty from recent geopolitical events, management noted FY26 is tracking in line with Street estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RTO:
- Rentokil Initial price target raised to 550 GBp from 500 GBp at Citi
- Rentokil Initial price target raised to 550 GBp from 520 GBp at Morgan Stanley
- Rentokil Initial Discloses GIC Stake Cut to 3.25% in March 2026
- Reiterating Buy on Rentokil Initial: Strong U.S. Outperformance, Terminix Integration Benefits, and Structural Pest Control Tailwinds Support Upside to 510p Target
- Rentokil Initial price target raised to 540 GBp from 500 GBp at RBC Capital